Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 197

Sort by

Sort Order Select

Journal Articles

Treatment Free Remission (TFR) “for” Pregnancy. Overview and Outcome of Pregnancies Reported in the Italy-Tfr Registry

Elisabetta Abruzzese, Elena Chiara, Maria Luisa Ferrari, Luigiana Luciano, Maria Cristina Miggiano, Sabrina Russo, Malgorzata Monika Trawinska, Maria Grazia Zampogna, Emanuele Koumantakis, Selene Grano, Valentina Bonuomo, Francesco Cavazzini, Paolo De Fabritiis, Carmen Fava

Blood (2023) 142 (Supplement 1): 4546.

https://doi.org/10.1182/blood-2023-187799

Published: 2023

Journal Articles

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

Blood (2023) 142 (Supplement 1): 4527.

https://doi.org/10.1182/blood-2023-181553

Published: 2023

Journal Articles

3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients

Blood (2023) 142 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2023-177619

Published: 2023

Journal Articles

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Blood (2023) 142 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2023-182220

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptom Burden Profile of Patients with Pre-Fibrotic and Overt Myelofibrosis: A Preliminary Report from the Gimema-Prophecy Observational Study

Blood (2023) 142 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2023-186429

Published: 2023

Journal Articles

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Franck E. Nicolini, Elisabetta Abruzzese, Gabrielle Roth-Guepin, Rami Abi-Tayeh, Vincent Alcazer, Sandrine Hayette, Stéphane Morisset, Françoise Huguet, Miriam Iezza, Fausto Castagnetti, Delphine Rea

Blood (2023) 142 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2023-178326

Published: 2023

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2023-188934

Published: 2023

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients

Simona Bernardi, Silvia Mutti, Alessia Cavalleri, Claudia Ielo, Mirko Farina, Federica Re, Katia Bosio, Alessandro Leoni, Cristian Bonvicini, Nicola Polverelli, Enrico Morello, Vera Radici, Massimo Breccia, Elisabetta Abruzzese, Michele Malagola, Domenico Russo

Blood (2023) 142 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2023-185733

Published: 2023

Journal Articles

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Blood (2023) 142 (Supplement 1): 628.

https://doi.org/10.1182/blood-2023-179141

Published: 2023

Journal Articles

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Alessandra Iurlo, Massimo Breccia, Fabio Stagno, Elisabetta Abruzzese, Fabrizio Pane, Immacolata Attolico, Paolo Sportoletti, Marco Cerrano, Sara Galimberti, Barbara Scappini, Maurizio Miglino, Sergio Siragusa, Isabella Capodanno, Diletta Valsecchi, Aurelio Pio Nardozza, Alessandra Misto, Paola Coco, Giuseppe Saglio, Gianantonio Rosti

Blood (2023) 142 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2023-180131

Published: 2023

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Discontinuation in Non-Allografted Ph+ Acute Lymphoblastic Leukemia Patients, a Campus ALL Real-Life Study

Matteo Dragani, Roberta Agrippino, Giovanna Rege Cambrin, Matteo Leoncin, Marco Cerrano, Prassede Salutari, Antonino Mulè, Cristina Papayannidis, Marzia Defina, Giulia Rivoli, Elisabetta Todisco, Elisabetta Abruzzese, Michele Cedrone, Nicola Fracchiolla, Fabio Guolo, Giuseppe Lanzarone, Robin Foà, Sabina Chiaretti

Blood (2023) 142 (Supplement 1): 2835.

https://doi.org/10.1182/blood-2023-187668

Published: 2023

Journal Articles

Extended Nutritional Monitoring in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia

Corrado Zuanelli Brambilla, Camilla Baldoni, Adele Santoni, Beatrice Esposito Vangone, Martina Simoncelli, Valentina Venanzi, Margherita Malchiodi, Elisabetta Abruzzese, Monica Bocchia

Blood (2023) 142 (Supplement 1): 1483.

https://doi.org/10.1182/blood-2023-184460

Published: 2023

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

Treatment-Free Remission in Ponatinib-Treated CML Patients: The Italy-Tfr Experience

Carmen Fava, Marco Santoro, Marianna Caramella, Elisabetta Abruzzese, Valentina Giai, Daniele Cattaneo, Chiara Elena, Mario Tiribelli, Mariella D'Adda, Giuseppina Loglisci, Valentina Bonuomo, Selene Grano, Jacqueline Ferrari, Federica Maria Catania, Ester Maria Pungolino, Alessandra Iurlo

Blood (2023) 142 (Supplement 1): 6385.

https://doi.org/10.1182/blood-2023-187230

Published: 2023

Journal Articles

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Roberto Latagliata, Alessandro Andriani, Massimo Breccia, Ida Carmosino, Federico Vozella, Atelda Romano, Annalisa Biagi, Luca Maurillo, Malgorzata Monika Trawinska, Katia Paciaroni, Michelina Santopietro, Sabrina Leonetti Crescenzi, Ada D'Addosio, Caterina Tatarelli, Elisabetta Abruzzese, Ambra Di Veroli, Elena Rossi, Valerio De Stefano, Marco Montanaro

Blood (2022) 140 (Supplement 1): 9691–9692.

https://doi.org/10.1182/blood-2022-165356

Published: 2022

Journal Articles

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood (2022) 140 (Supplement 1): 9688–9690.

https://doi.org/10.1182/blood-2022-157914

Published: 2022

Journal Articles

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Blood (2022) 140 (Supplement 1): 1504–1506.

https://doi.org/10.1182/blood-2022-162207

Published: 2022

Journal Articles

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Blood (2022) 140 (Supplement 1): 1498–1500.

https://doi.org/10.1182/blood-2022-159993

Published: 2022

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

NARROW

Treatment Free Remission (TFR) “for” Pregnancy. Overview and Outcome of Pregnancies Reported in the Italy-Tfr Registry

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Health-Related Quality of Life and Symptom Burden Profile of Patients with Pre-Fibrotic and Overt Myelofibrosis: A Preliminary Report from the Gimema-Prophecy Observational Study

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Tyrosine Kinase Inhibitor (TKI) Discontinuation in Non-Allografted Ph+ Acute Lymphoblastic Leukemia Patients, a Campus ALL Real-Life Study

Extended Nutritional Monitoring in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Treatment-Free Remission in Ponatinib-Treated CML Patients: The Italy-Tfr Experience

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only